Cancers, Free Full-Text
Por um escritor misterioso
Descrição
After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.
Cancer Text Magic, PDF
Cancer Free Posters for Sale
Destination Healthy Skin Toolkit - The Skin Cancer Foundation
Pathology Outlines - Carcinoma-general
Epigenetic regulation during cancer transitions across 11 tumour types
Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease - eBioMedicine
O Amar Mota Bou Get File - Colaboratory
Cancers, Free Full-Text
Journal of Cancer Research and Clinical Oncology
Dr 2.4.2 Dota 1 Free Download - Colaboratory
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
ROS in cancer therapy: the bright side of the moon
Dr 2.4.2 Dota 1 Free Download - Colaboratory
de
por adulto (o preço varia de acordo com o tamanho do grupo)
